When hrT-cell therapy leads to a decrease in tumor progression and metastasis, it is more relevant to refer to an adaptive immune response and the generation of activated mouse CD3+CD8+PD-1+ T-cells in the metastatic mouse model of LLC. The gene discussed is PDCD1; the disease is neoplasm.